InsidersTradesSigma
Follow the Applied Therapeutics Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Applied Therapeutics Inc. has logged 59 public disclosures. The latest transaction was filed on 22 December 2023 (Attribution). Among the most active insiders: Perfetti Riccardo. Every trade is free.
59
Insider Decl.
n/a
Thresholds
€2m
7 ops.
Buy Volume
€1m
14 ops.
Sell Volume
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 22 December 2023
Declarations59 total
450,000 shares0Common StockSEC:0001209191-23-059635:0
1,100,000 shares0Common StockSEC:0001209191-23-059636:0
400,000 shares0Common StockSEC:0001209191-23-059634:0
30,000 shares@ US$2.1789100.0% of flowCommon StockSEC:0001209191-23-057553:0
Canonical exit: 29 Feb 2024 (T+90)
3,968 shares@ US$1.971.7% of flowCommon StockSEC:0001209191-23-057117:0
1,583 shares@ US$1.972.0% of flowCommon StockSEC:0001209191-23-057116:0
965 shares@ US$1.971.5% of flowCommon StockSEC:0001209191-23-057115:0
575,000 sharesCommon StockSEC:0001035443-23-000327:0
300,000 shares0Common StockSEC:0001209191-23-056083:0
103,808 shares@ US$2.3211.8% of flowCommon StockSEC:0001035443-23-000315:0
155,000 shares@ US$2.4118.2% of flowCommon StockSEC:0001035443-23-000308:0
1,600,000 sharesCommon StockSEC:0001035443-23-000283:0
9,720 shares@ US$2.7021.6% of flowCommon StockSEC:0001209191-23-050890:0
115,632 shares@ US$2.7070.2% of flowCommon StockSEC:0001209191-23-050892:0
10,932 shares@ US$2.7019.7% of flowCommon StockSEC:0001209191-23-050891:0
12,375 shares@ US$1.059.5% of flowCommon StockSEC:0001209191-23-050097:0
20,000 shares0Common StockSEC:0001209191-23-035599:0
20,000 shares0Common StockSEC:0001209191-23-035598:0
20,000 shares0Common StockSEC:0001209191-23-035600:0
20,000 shares0Common StockSEC:0001209191-23-035596:0
20,000 shares0Common StockSEC:0001209191-23-035597:0
4,495 shares@ US$0.913.2% of flowCommon StockSEC:0001209191-23-003288:0
15,870 shares@ US$0.913.1% of flowCommon StockSEC:0001209191-23-003290:0
6,053 shares@ US$0.913.5% of flowCommon StockSEC:0001209191-23-003289:0
40,000 shares0Common StockSEC:0001209191-22-057759:0
25 of 59 declarations
关于 Applied Therapeutics Inc.
Applied Therapeutics Inc. 是一家在美国纳斯达克上市的临床阶段生物制药公司，专注于开发针对具有重大未满足医疗需求的罕见疾病的疗法。该公司成立于 2016 年 1 月，总部位于纽约，其战略围绕靶向已验证生物途径的新型候选药物，特别强调醛糖还原酶抑制 (ARI)。作为一家开发阶段的生物技术公司，Applied Therapeutics 迄今尚未有任何获批或商业化的药物，这意味着其股权故事主要由临床执行、监管进展和资本纪律驱动，而非经常性产品销售。([sec.gov](https://www.sec.gov/Archives/edgar/data/1697532/000095017025053840/aplt-20241231.htm?utm_source=openai)) 该公司的主要项目是 govorestat (AT-007)，一种 ARI 候选药物，正在推进用于经典半乳糖血症和其他罕见代谢疾病。Applied Therapeutics 还提及了 SORD 缺乏症和糖尿病并发症（包括糖尿病心肌病）的开发工作。该管线反映了专注的罕见病战略：Applied Therapeutics 并非作为一家广泛的商业制药公司进行竞争，而是针对定义明确的患者群体，这些群体治疗选择很少或没有，并且临床差异化可能具有重要意义。其科学定位基于早期靶向疾病生物学，使用生物标志物证明活性，并在适当情况下寻求可能加速的监管途径。([sec.gov](https://www.sec.gov/Archives/edgar/data/1697532/000095017025053840/aplt-20241231.htm?utm_source=openai)) 从竞争角度来看，Applied Therapeutics 在一个高度专业化的领域运营，成功取决于疗效、耐受性和监管接受度的证明。可寻址市场相对较小，但如果公司能够在孤儿适应症中建立明确的临床益处，它们可能具有商业吸引力。同时，风险状况较高。FDA 于 2024 年 11 月对 govorestat 在经典半乳糖血症方面发出了完整回复函，这突显了投资案例的二元性质以及对后续开发、重新提交或替代监管策略的依赖。([sec.gov](https://www.sec.gov/Archives/edgar/data/1697532/000095017025053840/aplt-20241231.htm?utm_source=openai)) 在运营方面，Applied Therapeutics 总部位于美国纽约，其地理足迹主要仍在美国，尽管其罕见病项目如果临床数据支持批准，最终可能具有更广泛的国际相关性。公司近期发展包括 2025 年高管领导层变动，特别是 Evan Bailey 医学博士晋升为首席医疗官，公司继续推进其罕见病产品组合。对于投资者而言，APLT 应被视为一家投机性的纳斯达克上市公司，其管线集中，临床和监管风险高，潜在上行空间与在利基代谢疾病适应症中成功执行相关。([ir.appliedtherapeutics.com](https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-key-leadership-appointments/?utm_source=openai))
